Laboratorios Farmaceuticos ROVI SA news

   Watch this stock
Showing stories 1 - 10 of about 19   

Articles published

ROVI 11.72 -0.12 (-1.01%)
price chart
Orexigen Therapeutics Announces Commercialization and Distributorship ...
SAN DIEGO, Aug. 1, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that wholly owned subsidiary Orexigen Therapeutics Ireland Ltd.
Laboratorios Farmac�uticos Rovi SA adopta la tecnolog�a en la nube con Veeva CRM
La compa��a farmac�utica especializada Laboratorios Farmac�uticos Rovi SA (Rovi) ha luchado por encontrar un nuevo sistema de gesti�n de relaci�n con el cliente (CRM) m�s �gil que sustituyese su desfasada tecnolog�a.
Related articles »  
Laboratorios Farmac�uticos taps Veeva for cloud-based CRM
Spanish pharmaceuticals company Laboratorios Farmac�uticos Rovi (Rovi) has tapped Veeva's cloud-based CRM in a bid to replace its existing on premise solution, the company announced today.
Related articles »  
Deep Vein Thrombosis (DVT) Pipeline Review, H2 2016 - Analysis of 6 Companies ...
Deep Vein Thrombosis (DVT) pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.
Global Schizophrenia Pipeline Review, H1 2016 - Analysis, Technologies ...
The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Deep Vein Thrombosis Therapeutic Pipeline Market Review, H2 2016
info-page-182 The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) ...
Rovi names former Ericsson exec Pete Thompson as chief operating officer
S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed.
Orexigen Therapeutics Reports Business and Financial Results for the Second ...
SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2016.
Francisco Parames' Bestinver Asset Management Quarterly Newsletter July 2013
Among the most noteworthy rises in the portfolio, we should point out Laboratorios Almirall (+33%), Semapa (+19%), Gas Natural (+17%), Laboratorios Farmac�uticos Rovi (+31%), Zon Multimedia (+29%), Altri (+19%), Antena3 (+55%) and Mediaset (+31%). This ...
Related articles »  
TiVo's stock soars in active trade after report of merger talks
Shares of TiVo Inc. TIVO, -1.01% soared 17% in active morning trade Thursday to a 3 1/2-month high, after a report that the maker of digital video recorders was in merger talks.